These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1761736)

  • 21. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.
    Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L
    Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinidine does not alter antipyrine metabolism.
    Bowles SK; Cardozo L; Edwards DJ
    J Clin Pharmacol; 1990 Mar; 30(3):267-71. PubMed ID: 2312782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disposition of antipyrine in patients with extensive metastatic liver disease.
    Robertz-Vaupel GM; Lindecken KD; Edeki T; Funke C; Belwon S; Dengler HJ
    Eur J Clin Pharmacol; 1992; 42(5):465-9. PubMed ID: 1606991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of enzyme induction on antipyrine metabolite formation.
    Danhof M; Verbeek RM; van Boxtel CJ; Boeijinga JK; Breimer DD
    Br J Clin Pharmacol; 1982 Mar; 13(3):379-86. PubMed ID: 7059438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of age and sex on metabolism and urinary excretion of antipyrine.
    Jorquera F; Almar M; Pozuelo M; Sansegundo D; González-Sastre M; González-Gallego J
    J Gerontol A Biol Sci Med Sci; 1998 Jan; 53(1):M14-9. PubMed ID: 9467428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simplified test for determination of drug-oxidizing capacity in rats with chemical-induced liver injury using caffeine and trimethadione as model drugs.
    Tanaka E; Ishikawa A; Misawa S
    Pharmacol Toxicol; 1992 Mar; 70(3):177-80. PubMed ID: 1579543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state.
    Teunissen MW; De Leede LG; Boeijinga JK; Breimer DD
    J Pharmacol Exp Ther; 1985 Jun; 233(3):770-5. PubMed ID: 4009489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic drug clearance in patients with mild cystic fibrosis.
    Kearns GL; Crom WR; Karlson KH; Mallory GB; Evans WE
    Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.
    Danhof M; Krom DP; Breimer DD
    Xenobiotica; 1979 Nov; 9(11):695-702. PubMed ID: 119355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impairment of antipyrine clearance in humans by propranolol.
    Greenblatt DJ; Franke K; Huffman DH
    Circulation; 1978 Jun; 57(6):1161-64. PubMed ID: 639239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of flumethrin on hepatic drug-metabolizing enzymes and antipyrine disposition in rats.
    Anadón A; Martinez-Larrañaga MR; Diaz MJ; Bringas P; Fernandez MC; Martinez MA; Fernandez-Cruz ML
    Toxicol Appl Pharmacol; 1995 May; 132(1):14-8. PubMed ID: 7747277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of spironolactone on antipyrine metabolism in calves.
    Janus K; Suszycka J
    Res Vet Sci; 1996 Jul; 61(1):87-8. PubMed ID: 8819201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of a subclinical fascioliasis on antipyrine clearance and metabolite excretion in sheep.
    Tufenkji AE; Alvinerie M; Pineau T; Boulard C; Galtier P
    Xenobiotica; 1988 Apr; 18(4):357-64. PubMed ID: 3400265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipyrine clearance and metabolism in patients with psoriasis.
    Kubota K; Ishizaki T; Chiba K; Takagi A; Nakagawa A; Nakamura K
    Br J Clin Pharmacol; 1986 Oct; 22(4):455-62. PubMed ID: 3768257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in metabolism and urinary excretion of antipyrine induced by aerobic conditioning.
    Villa JG; Bayon JE; González-Gallego J
    J Sports Med Phys Fitness; 1999 Sep; 39(3):197-201. PubMed ID: 10573660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex-related differences in hepatic drug-oxidizing capacity of streptozotocin-induced diabetic rats.
    Tanaka E; Ishikawa A; Misawa S; Kuroiwa Y
    J Pharmacobiodyn; 1988 Jun; 11(6):416-23. PubMed ID: 3050023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual effects of a novel thienodiazepine platelet-activating factor antagonist, on drug-oxidizing enzymes in beagle dog.
    Tanaka E; Daling Z; Abe K; Nakamura T; Horie T
    Xenobiotica; 1994 Apr; 24(4):293-300. PubMed ID: 8059533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elimination of antipyrine and its metabolites in interferon treated hepatitis C.
    Sieck JO; el-Yazigi A; Ali H; Døssing M; Saour J; Raines DA; Ernst P
    Hum Exp Toxicol; 1994 Sep; 13(9):598-601. PubMed ID: 7986571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of 9-hydroxyellipticine and 3-methylcholanthrene treatment on antipyrine metabolite formation in rats in vivo.
    Teunissen MW; Joeres RP; Vermeulen NP; Breimer DD
    Xenobiotica; 1983 Apr; 13(4):223-31. PubMed ID: 6624137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and indocyanine green clearances.
    Rocci ML; Vlasses PH; Lener ME; Fruncillo RA; Sirgo MA
    J Clin Pharmacol; 1989 Oct; 29(10):891-5. PubMed ID: 2592580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.